KR100405161B1 - Pharmaceutical composition for intramuscular injection containing loxoprofen - Google Patents

Pharmaceutical composition for intramuscular injection containing loxoprofen Download PDF

Info

Publication number
KR100405161B1
KR100405161B1 KR10-2000-0076298A KR20000076298A KR100405161B1 KR 100405161 B1 KR100405161 B1 KR 100405161B1 KR 20000076298 A KR20000076298 A KR 20000076298A KR 100405161 B1 KR100405161 B1 KR 100405161B1
Authority
KR
South Korea
Prior art keywords
sodium
injection
composition
roxofene
intramuscular injection
Prior art date
Application number
KR10-2000-0076298A
Other languages
Korean (ko)
Other versions
KR20020046407A (en
Inventor
이성태
한신
박우일
주정철
이철규
김혜선
Original Assignee
신풍제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2000-0076298A priority Critical patent/KR100405161B1/en
Application filed by 신풍제약주식회사 filed Critical 신풍제약주식회사
Priority to CNB018049494A priority patent/CN1278672C/en
Priority to APAP/P/2002/002594A priority patent/AP1530A/en
Priority to JP2002549235A priority patent/JP2004515526A/en
Priority to BR0108313-9A priority patent/BR0108313A/en
Priority to UA2002086717A priority patent/UA76097C2/en
Priority to MXPA02007788A priority patent/MXPA02007788A/en
Priority to PCT/KR2001/002161 priority patent/WO2002047661A1/en
Priority to OA1200200244A priority patent/OA12175A/en
Priority to AU2002222750A priority patent/AU2002222750A1/en
Priority to RU2002121772/15A priority patent/RU2232572C2/en
Priority to ARP010105804A priority patent/AR033596A1/en
Publication of KR20020046407A publication Critical patent/KR20020046407A/en
Application granted granted Critical
Publication of KR100405161B1 publication Critical patent/KR100405161B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 유효성분으로서 우수한 소염진통 효과를 갖는 하기 화학식 1의 록소프로펜(loxoprofen) 또는 그의 약제학적으로 허용되는 염을 함유하는 근육주사제 조성물에 관한 것이다:The present invention relates to an intramuscular injection composition containing loxoprofen of formula (1) or a pharmaceutically acceptable salt thereof having excellent anti-inflammatory analgesic effect as an active ingredient:

[화학식 1][Formula 1]

Description

록소프로펜 함유 근육주사제 조성물{Pharmaceutical composition for intramuscular injection containing loxoprofen}Pharmaceutical composition for intramuscular injection containing loxoprofen}

본 발명은 록소프로펜(loxoprofen)의 신규한 제제에 관한 것이다. 보다 구체적으로, 본 발명은 유효성분으로서 우수한 소염진통 효과를 갖는 록소프로펜 또는 그의 약제학적으로 허용되는 염을 함유하는 근육주사용 제제에 관한 것이다.The present invention relates to a novel formulation of loxoprofen. More specifically, the present invention relates to an intramuscular injection formulation containing roxofene or a pharmaceutically acceptable salt thereof having excellent anti-inflammatory analgesic effect as an active ingredient.

록소프로펜(화학명: 2-[4-(2-옥소사이클로펜틸)페닐]프로피온산)은 하기 화학식 1로 표시되는 프로피온계 비스테로이드성 소염진통제(NSAID)로서, 주로 록소프로펜의 나트륨염 형태, 즉 록소프로펜 나트륨(loxoprofen Na)으로 사용되고 있다:Roxopropene (chemical name: 2- [4- (2-oxocyclopentyl) phenyl] propionic acid) is a propion-based nonsteroidal anti-inflammatory analgesic agent (NSAID) represented by the following general formula (1), which is mainly a sodium salt of roxofene It is used in the form ie loxoprofen Na:

록소프로펜 나트륨은 만성관절류마티스, 변형성관절증, 요통증, 견관절주위염, 경견완증후군에 효과적이며, 그밖에도 수술후, 외상후 및 발치후 통증에도 효과적인 것으로 알려져 있으며, 현재 경구용 정제(tablet)로 널리 사용되고 있다.Loxoprofen Sodium is effective for chronic arthritis, deformed arthrosis, low back pain, periarthritis of the shoulder, and systolic syndrome. In addition, it is known to be effective for pain after surgery, post-traumatic and post-treatment. It is used.

이 약물은 타 프로피온산계 비스테로이드성 소염진통제에 비해 위장장애가 비교적 적지만 장기 복용시에는 위장장애나 소화성궤양 등의 부작용을 일으키게 되므로, 최근에는 서방성 경피용 첩부제 등의 경피투여제제로 개발하기 위한 연구가 진행되고 있다[PCT/JP1997/02936, 한국특허출원 제98-41351호(1998. 10. 1), 미국특허 제4,740,374호(1988. 4. 26), PCT/WO95/16440(1995. 6. 22), 한국특허출원 제96-38430호(1996. 9. 5) 등]. 그러나, 이러한 경피투여제제의 경우, 경구투여가 곤란하거나 장기간의 경구투여가 필요한 환자에게 투여에 따른 부작용이나 불편을 경감시킬 수 있다는 측면은 있지만, 이 또한 기존의 경피용 첩부제들과 마찬가지로 고분자 등으로 이루어진 경피흡수제제로 사용되므로 장시간의 피부(경피) 부착에 따른 발진 또는 가려움 등의 피부 알러지 증상을 유발할 수 있으며, 환자의 활동에도 불편을 주는 등 또다른 부작용을 수반하게 된다. 또한, 피부를 통한 약물의 흡수속도를 조절할 수 있다고는 하나, 통증부위와 개개인의 체질에 따라 약물의 경피투여속도나 흡수량이 상이하여 기대하는 수준의 치료효과를 얻기에는 장시간이 소요되므로 통증이 심한 응급 환자에게는 사용할 수 없다는 단점이 있다.This drug has less gastrointestinal disorders than other propionic acid nonsteroidal anti-inflammatory drugs, but when taken for a long time, it causes side effects such as gastrointestinal disorders and peptic ulcer. Therefore, it has recently been developed as a transdermal drug such as a sustained release transdermal patch. Research is being conducted [PCT / JP1997 / 02936, Korean Patent Application No. 98-41351 (October 1, 1998), US Patent No. 4,740,374 (April 26, 1988), PCT / WO95 / 16440 (1995. 6. 22), Korean Patent Application No. 96-38430 (September 5, 1996). However, in the case of such transdermal drugs, there are aspects that can reduce side effects or discomfort associated with the administration to patients who have difficulty in oral administration or require long-term oral administration, but also like polymers such as conventional transdermal patches. Since it is used as a transdermal absorption agent, it may cause allergic symptoms such as rash or itching due to prolonged skin (transdermal) adhesion, and may cause other side effects such as discomfort in the activity of the patient. In addition, although the rate of absorption of the drug through the skin can be controlled, depending on the pain area and the individual's constitution, the transdermal administration rate or absorption of the drug is different, so it takes a long time to obtain the expected therapeutic effect. The disadvantage is that it can not be used for emergency patients.

한편, 록소프로펜 나트륨은 널리 알려져 있는 프로피온계 비스테로이드성 소염진통제인 케토프로펜(ketoprofen) 또는 이부프로펜(ibuprofen) 등과는 상이한 작용기전을 가지며, 염증과 통증의 원인물질인 프로스타글란딘(prostaglandin)의 생합성을 억제함으로써 뛰어난 소염진통 효과를 나타낸다. 즉, 이 약물은 프로드럭(pro-drug)으로서, 경구투여시 체내에서 케톤환원효소에 의해 대사되어 트랜스-OH 대사체, 즉 2-[파라-(트랜스-2-하이드록시사이클로펜틸)페닐]프로피온산이 되며, 이 대사체가 프로스타글란딘 생성효소인 사이클로옥시게나아제(cyclooxygenase)에 대한 저해활성을 통해 우수한 소염진통 효과를 나타내는 것이다[Matsuda et. al., Japanese Journal of Inflammation, Vol. 2, No. 3, Summer, pp263-266(1983)]. 이때 케톤환원효소는 주로 간장이나 신장에 존재하여[Tanaka et. al., Japanese Journal of Inflammation, Vol. 3, No. 2, Spring, pp151-155(1983)] 경구투여시에 록소프로펜 나트륨을 트랜스-OH 대사체로 대사시켜 강한 소염진통 작용을 나타냄으로써 그 약효를 발휘하며, 피부에도 이 효소가 존재하여 동일한 약효를 나타내는 것으로 알려져 있다[미국특허 제4,740,374호(1988. 4. 26)]. 이러한 이유로, 록소프로펜 또는 그의 약제학적으로 허용되는 염을 유효성분으로 하는 정제 등과 같은 경구투여용 제제는 상품화되어 널리 판매되고 있고[록소닌(Loxonin) 또는 록스펜(Loxfen)], 최근에는 외용제제, 즉 경피투여용 첩부제 또는 패취제제 등에 대한 연구가 진행되고 있으나, 아직까지 이 약물의 근육주사제(intramuscular injection)에 대해서는 보고된 바가 전혀 없다.On the other hand, lysopropene sodium has a different mechanism of action from the well-known propion-based nonsteroidal anti-inflammatory drugs, ketoprofen or ibuprofen, and the prostaglandin, a substance that causes inflammation and pain. By suppressing biosynthesis, excellent anti-inflammatory analgesic effect is shown. In other words, the drug is a pro-drug that is metabolized by ketone reductase in the body upon oral administration, resulting in a trans-OH metabolite, namely 2- [para- (trans-2-hydroxycyclopentyl) phenyl] It becomes propionic acid, and this metabolite shows excellent anti-inflammatory analgesic effect through inhibitory activity against cyclooxygenase, a prostaglandin synthase [Matsuda et. al., Japanese Journal of Inflammation, Vol. 2, No. 3, Summer, pp 263-266 (1983). Ketone-reductase is mainly present in the liver or kidney [Tanaka et. al., Japanese Journal of Inflammation, Vol. 3, No. 2, Spring, pp151-155 (1983)] It shows its anti-inflammatory effect by metabolizing roxofene sodium into trans-OH metabolite during oral administration and shows strong anti-inflammatory analgesic effect. It is known to represent (US Pat. No. 4,740,374 (April 26, 1988)). For this reason, oral preparations such as tablets using roxofene or a pharmaceutically acceptable salt thereof as an active ingredient have been commercialized and widely sold (Loxonin or Loxfen), and recently, There are studies on external preparations, namely, transdermal patch or patch, but there has been no report on intramuscular injection of the drug.

이상 언급한 바와 같이, 기존에 개발완료된 록소프로펜 경구투여제제의 경우, 음식물 섭취가 어려운 중증 환자나 위장장애가 있는 환자 등에게는 사용하기가 곤란하며, 현재 많은 연구가 진행중인 경피흡수를 통한 패취제 등의 경우, 아직 개발이 완료되지 못하였음은 물론 외용제제로 개발된다 할지라도 약물의 피부투과를 위한 흡수촉진제 등과 같은 많은 보조제를 사용해야 하므로 이에 따른 피부 발진 등의 또다른 부작용이 수반될 수 있고 장시간 해당 신체부위에 부착하고 있어야 함에 따라 행동상 제약이 따르는 등 많은 불편을 초래할 수 있다. 특히, 염증이나 통증 증상은 대부분 관절부위에서 일어나므로 패취형의 경피흡수 외용제제는 부착후 활동시 관절의 운동에 의해 피부에서 외용제제가 쉽게 떨어져나가는 등 원하는 약효를 지속적으로 나타내는데 많은 어려움이 따를 것으로 예상된다.As mentioned above, in the case of the previously developed orally administered loxoprofen, it is difficult to use in patients with severe or difficult gastrointestinal disorders, and a lot of researches are being carried out through transdermal absorption. In the case of such a case, the development has not been completed yet, and even if it is developed as an external preparation, many supplements such as absorption accelerators for skin penetration of the drug must be used, which may result in other side effects such as skin rashes. Being attached to the body can cause a lot of inconvenience, including behavioral restrictions. In particular, since most of the inflammation and pain symptoms occur in the joint area, the patch-type transdermal absorption topical preparations are expected to have a lot of difficulties in continuously displaying the desired medicinal effects such as the external preparations easily come off from the skin by the movement of the joints during the activity after attachment. .

따라서, 경구투여가 어려운 환자에게 적용할 수 있을뿐 아니라 경피투여시 수반되는 제문제점들을 해결할 수 있는 새로운 록소프로펜 제제의 개발이 절실히 요청되어 왔다.Therefore, there has been a great demand for the development of new roxofene formulations that can be applied to patients who have difficulty in oral administration as well as solve problems associated with transdermal administration.

이에, 본 발명자들은 신규 록소프로펜 제제를 개발해내기 위하여 지속적인 연구를 수행해왔으며, 그 결과, 록소프로펜 나트륨이 피부는 물론 근육내에서도 케톤환원효소에 의해 트랜스-OH 대사체로 전환되어 우수한 소염진통 효과를 나타낼 수 있다는 새롭고도 놀라운 사실을 확인하였다. 이러한 사실을 기초로 하여, 본 발명자들은 록소프로펜의 근육주사제가 경구투여가 곤란한 환자에게도 적용가능할뿐 아니라, 경구투여시보다 소량의 약물로도 동등 이상의 소염진통 효과를 얻을 수 있으며, 경피투여시 수반되는 부작용을 해소함과 동시에 속효성을 얻을 수 있음을 확인하고, 본 발명을 완성하기에 이르렀다.Therefore, the present inventors have conducted continuous research to develop a novel roxofene penetrate formulation, and as a result, it is converted to trans-OH metabolite by ketone reductase in the skin as well as in the muscle, and excellent anti-inflammatory pain. New and surprising facts can be found. On the basis of this fact, the present inventors can not only apply the intramuscular injection of Roxoprofen to patients with difficulty in oral administration, but also obtain an anti-inflammatory effect equivalent to or more with a small amount of drugs than when administered orally. It was confirmed that the effect can be obtained at the same time to solve the side effects accompanying the time, to complete the present invention.

도 1은 록소프로펜 정제 및 근육주사제의 약물혈중농도 비교분포곡선이다.1 is a comparative distribution curve of drug blood concentrations of roxofene tablets and intramuscular injections.

본 발명은 유효성분으로서 하기 화학식 1의 록소프로펜 또는 그의 약제학적으로 허용되는 염을 함유하는 근육주사제 조성물에 관한 것이다:The present invention relates to an intramuscular injection composition containing Roxoprofen of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:

[화학식 1][Formula 1]

본 발명의 조성물에 있어서, 록소프로펜의 약제학적으로 허용되는 염은 록소프로펜의 나트륨염인 것이 바람직하다.In the composition of the present invention, the pharmaceutically acceptable salt of roxofene is preferably the sodium salt of roxofene.

이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.

이상 설명한 바와 같이, 록소프로펜 또는 그의 약제학적으로 허용되는 염은 경구투여시 위장관에서는 불활성체로 흡수되어 간장 또는 신장에서 케톤환원효소에 의해 트랜스-OH 대사체로 전환되고, 경피투여시 피부에서도 케톤환원효소에 의해 트랜스-OH 대사체로 전환되어, 비로소 우수한 소염진통 효과를 나타내는 것으로 보고되어 있다. 그러나, 본 발명자들은 피부뿐만 아니라 근육내에서도 상기 약물이 케톤환원효소에 의해 트랜스-OH 대사체로 전환됨으로써 우수한 소염진통 효과를 나타낼 수 있으며, 특히 상기 약물을 근육주사에 의해 투여함으로써, 경구투여시 보다 소량, 예를들어, 정제 복용량의 1/2∼2/3의 양으로도 동등 이상의 효과를 거둘 수 있음을 확인하였다. 또한, 통증환자의 치료시 최우선적으로 요구되는 효과가 바로 소염진통 효과이므로, 이러한 근육주사제의 개발을 통해 상기 목적에 부합하는 속효성도 얻을 수 있음을 확인하였다.As described above, roxofene or a pharmaceutically acceptable salt thereof is absorbed as an inactive substance in the gastrointestinal tract upon oral administration, converted to trans-OH metabolites by ketone reductase in the liver or kidney, and also in the skin during transdermal administration. It has been reported to convert to trans-OH metabolites by reductase, which shows an excellent anti-inflammatory analgesic effect. However, the present inventors can exhibit an excellent anti-inflammatory analgesic effect by converting the drug into trans-OH metabolites by ketone reductase not only in the skin but also in the muscle, and in particular, by administering the drug by intramuscular injection, For example, it was confirmed that even an amount equal to or greater than 1/2 to 2/3 of the tablet dosage can be achieved. In addition, since the anti-inflammatory analgesic effect is the first required effect in the treatment of pain patients, it was confirmed that through the development of such intramuscular injections can also obtain a fast-acting effect that meets the purpose.

따라서, 본 발명은 기존의 정제 등과 같은 경구용 제제가 갖는, 경구투여가 곤란한 환자에 대한 사용제한 및 장기간 복용시 위장장애 등과 같은 부작용 유발, 및 경피용 첩부제 등과 같은 외용제제가 갖는 사용상의 불편함 및 피부 알러지 유발 등으로 인해, 사용에 제한을 받아왔거나, 특히 빠른 약효를 기대하는 환자들을 위해 편리하게 사용될 수 있는 록소프로펜의 근육주사용 제제에 관한 것이다.Therefore, the present invention is inconvenient in the use of oral preparations, such as tablets, such as restrictions on use for patients with difficulty in oral administration, causing side effects such as gastrointestinal disorders during long-term administration, and external preparations such as transdermal patches. And intramuscular formulations of loxoprofen, which may have been constrained for use due to skin allergy or the like or may be conveniently used, especially for patients expecting fast drug efficacy.

본 발명에 따른 록소프로펜의 근육주사제는 적절한 처방으로 제조될 수 있으며, 주사제 처방의 유통에 따른 제품 안정성을 확보하기 위하여, 주사제로 사용가능한 산수용액 또는 인산염 등의 완충용액을 사용하여 pH를 조절함으로써, 물리적 으로나 화학적으로 매우 안정한 주사제로 제조될 수 있다.Injectable intramuscular injection of loxoprofen according to the present invention can be prepared by a suitable prescription, in order to ensure product stability according to the distribution of the injection formulation, pH by using a buffer solution such as an aqueous solution or phosphate that can be used as an injection By adjusting, it can be prepared into injections which are very stable both physically and chemically.

보다 구체적으로, 본 발명의 조성물은 록소프로펜 또는 그의 약제학적으로 허용되는 염을 안정화제 또는 용해보조제와 함께 주사용수에 용해시킨후 멸균처리, 특히, 고온감압멸균법 또는 무균여과법에 의해 멸균처리하여 제조될 수 있다. 상기 주사용수로는 주사용 증류수 또는 주사용 완충용액, 예를들어, pH 3.5∼7.5 범위의 인산염 완충용액 또는 인산이수소나트륨(NaH2PO4)-구연산 완충용액을 사용할 수 있다. 사용되는 인산염은 나트륨염 또는 칼륨염 형태이거나 무수물 또는 수화물 형태이어도 무방하고, 구연산 또한 무수물 또는 수화물 형태이어도 무방하다.More specifically, the composition of the present invention is dissolved in lysopropene or a pharmaceutically acceptable salt thereof in water for injection with a stabilizer or dissolution aid and then sterilized by sterilization, in particular, by autoclaving or aseptic filtration. Can be prepared. As the water for injection, distilled water for injection or buffer for injection, for example, a phosphate buffer solution in the range of pH 3.5 to 7.5 or sodium dihydrogen phosphate (NaH 2 PO 4 ) -citric acid buffer solution can be used. The phosphates used may be in the form of sodium or potassium salts or in the form of anhydrides or hydrates, and in the form of citric acid or anhydrides or hydrates.

한편, 본 발명에서 사용되는 안정화제는 나트륨 피로설파이트(sodium pyrosulfite), 중아황산나트륨(NaHSO3), 메타중아황산나트륨(Na2S2O3) 또는 에틸렌디아민테트라아세트산(ethylenediaminetetraacetic acid)을 포함하고, 용해보조제는 수산화나트륨(NaOH), 탄산수소나트륨(NaHCO3), 탄산나트륨(NaCO3) 또는 수산화칼륨(KOH)과 같은 염기, 또는 염산(HCl) 또는 아세트산(CH3COOH)과 같은 산을 포함하는 것이다.Meanwhile, the stabilizer used in the present invention includes sodium pyrosulfite, sodium bisulfite (NaHSO 3 ), sodium metabisulfite (Na 2 S 2 O 3 ) or ethylenediaminetetraacetic acid, Dissolution aids include bases such as sodium hydroxide (NaOH), sodium bicarbonate (NaHCO 3 ), sodium carbonate (NaCO 3 ) or potassium hydroxide (KOH), or acids such as hydrochloric acid (HCl) or acetic acid (CH 3 COOH). will be.

본 발명에 따른 조성물은 pH 3.5∼7.5 범위의 액제 조성물이거나, 멸균처리후 동결건조시켜 제조되는 분말 조성물인 것이 바람직하며, 유효성분의 농도는 2∼20% 범위인 것이 바람직하다.The composition according to the invention is preferably a liquid composition in the range of pH 3.5 to 7.5, or a powder composition prepared by lyophilization after sterilization, the concentration of the active ingredient is preferably in the range of 2 to 20%.

본 발명을 하기 실시예에 의해 더욱 구체적으로 설명하지만, 이들에 의해 본 발명의 범위가 어떤 식으로든 제한되는 것은 아니다.The present invention will be described in more detail with reference to the following examples, which, however, are not intended to limit the scope of the invention in any way.

주사제의 제조Preparation of Injectables

실시예 1:Example 1:

록소프로펜 나트륨과 나트륨 피로설파이트를 주사용 증류수에 용해시킨후 고온감압멸균법으로 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 1).The intramuscular injection was made by dissolving roxofene sodium and sodium pyrosulphite in distilled water for injection and then sterilizing by autoclaving in a 1 ml ampoule (Table 1).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.2%(W/V)0.2% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 2:Example 2:

록소프로펜 나트륨과 아황산나트륨를 주사용 증류수에 용해시킨후 pH가 6이 되도록 묽은 염산을 첨가하고 고온감압멸균법 또는 무균여과법에 의해 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 2).Muscle injection was prepared by dissolving roxofene sodium and sodium sulfite in distilled water for injection, adding dilute hydrochloric acid to a pH of 6, and sterilizing the solution by sterilization by autoclaving or aseptic filtration in 1 ml ampoule. Table 2).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.1%(W/V)0.1% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml 묽은 염산Dilute hydrochloric acid 적량(pH 6으로 조절)Appropriate (adjust with pH 6)

실시예 3:Example 3:

록소프로펜 나트륨과 나트륨 피로설파이트를 주사용 증류수에 용해시킨후 pH가 5가 되도록 묽은 염산을 첨가하고 고온감압멸균법 또는 무균여과법에 의해 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 3).After dissolving roxofene sodium and sodium pyrosulphite in distilled water for injection, dilute hydrochloric acid was added to pH 5 and sterilized by autoclaving or aseptic filtration into a 1 ml ampoule Prepared (Table 3).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.1%(W/V)0.1% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml 묽은 염산Dilute hydrochloric acid 적량(pH 5로 조절)Dose (adjusted to pH 5)

실시예 4:Example 4:

록소프로펜 나트륨과 메타중아황산나트륨을 주사용 증류수에 용해시킨후 pH가 4가 되도록 묽은 염산을 첨가하고 고온감압멸균법 또는 무균여과법에 의해 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다.After dissolving roxofene sodium and sodium metabisulfite in distilled water for injection, dilute hydrochloric acid was added to pH 4, and the solution obtained by sterilization by high-temperature autoclaving or aseptic filtration was filled into 1 ml ampoules to prepare an intramuscular injection. It was.

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 메타중아황산나트륨(Na2S2O5)Sodium metabisulfite (Na 2 S 2 O 5 ) 0.2%(W/V)0.2% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml 묽은 염산Dilute hydrochloric acid 적량(pH 4로 조절)Dose (adjusted to pH 4)

실시예 5:Example 5:

인산이수소칼륨과 수산화나트륨을 주사용 증류수에 용해시켜 pH 6.5의 인산염 완충용액을 제조하였다. 제조된 인산염 완충용액에 록소프로펜 나트륨과 나트륨 피로설파이트를 용해시킨후 고온감압멸균법 또는 무균여과법에 의해 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 5).Potassium dihydrogen phosphate and sodium hydroxide were dissolved in distilled water for injection to prepare a phosphate buffer at pH 6.5. Muscle injection was prepared by dissolving roxofene sodium and sodium pyrosulphite in the prepared phosphate buffer and then sterilizing the solution by autoclaving or aseptic filtration in 1 ml ampoule (Table 5).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.2%(W/V)0.2% (W / V) 인산이수소칼륨(KH2PO4)Potassium Dihydrogen Phosphate (KH 2 PO 4 ) 0.68%(W/V)0.68% (W / V) 수산화나트륨(NaOH)Sodium Hydroxide (NaOH) 0.06%(W/V)0.06% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 6:Example 6:

인산이수소나트륨·십이수화물과 구연산을 주사용 증류수에 용해시켜 pH 5.4의 인산이수소나트륨-구연산 완충용액을 제조하였다. 제조된 완충용액에 록소프로펜 나트륨과 나트륨 피로설파이트를 용해시킨후 고온감압멸균법 또는 무균여과법에 의해 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 6).Sodium dihydrogen phosphate, dihydrate and citric acid were dissolved in distilled water for injection to prepare a sodium dihydrogen phosphate-citric acid buffer solution of pH 5.4. Muscle injection was prepared by dissolving roxofene sodium and sodium pyrosulphite in the prepared buffer and then sterilizing the solution by sterilization by autoclaving or aseptic filtration in a 1 ml ampoule (Table 6).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.2%(W/V)0.2% (W / V) 인산이수소나트륨·십이수화물(NaH2PO4·12H2O)Sodium dihydrogen phosphate, dihydrate (NaH 2 PO 4 12H 2 O) 1.45%(W/V)1.45% (W / V) 구연산Citric acid 0.53%(W/V)0.53% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 7:Example 7:

인산이수소칼륨과 무수 인산일수소나트륨을 주사용 증류수에 용해시켜 pH 6.8의 인산염 완충용액을 제조하였다. 제조된 완충용액에 록소프로펜 나트륨과 나트륨 피로설파이트를 용해시킨후 고온감압멸균법으로 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 7).Potassium dihydrogen phosphate and anhydrous sodium dihydrogen phosphate were dissolved in distilled water for injection to prepare a phosphate buffer at pH 6.8. After dissolving roxofene sodium and sodium pyrosulphite in the prepared buffer solution, the solution obtained by sterilization by autoclaving was filled in 1 ml ampoule to prepare a muscle injection (Table 7).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.2%(W/V)0.2% (W / V) 인산이수소칼륨(KH2PO4)Potassium Dihydrogen Phosphate (KH 2 PO 4 ) 0.34%(W/V)0.34% (W / V) 무수 인산일수소나트륨(Na2HPO4)Anhydrous Sodium Dihydrogen Phosphate (Na 2 HPO 4 ) 0.34%(W/V)0.34% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 8:Example 8:

인산이수소칼륨과 수산화나트륨을 주사용 증류수에 용해시켜 pH 7.0의 인산염 완충용액을 제조하였다. 제조된 완충용액에 록소프로펜 나트륨과 나트륨 피로설파이트를 용해시킨후 고온감압멸균법으로 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 8).Potassium dihydrogen phosphate and sodium hydroxide were dissolved in distilled water for injection to prepare a phosphate buffer at pH 7.0. After dissolving sodium roxofene and sodium pyrosulphite in the prepared buffer solution, the solution obtained by sterilization by autoclaving was filled in 1 ml ampoules to prepare a muscle injection (Table 8).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.2%(W/V)0.2% (W / V) 인산이수소칼륨(KH2PO4)Potassium Dihydrogen Phosphate (KH 2 PO 4 ) 0.68%(W/V)0.68% (W / V) 수산화나트륨(NaOH)Sodium Hydroxide (NaOH) 0.12%(W/V)0.12% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 9:Example 9:

인산이수소칼륨과 수산화나트륨을 주사용 증류수에 용해시켜 pH 7.4의 인산염 완충용액을 제조하였다. 제조된 완충용액에 록소프로펜 나트륨과 나트륨 피로설파이트를 용해시킨후 고온감압멸균법으로 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 9).Potassium dihydrogen phosphate and sodium hydroxide were dissolved in distilled water for injection to prepare a phosphate buffer at pH 7.4. After dissolving sodium roxofene and sodium pyrosulphite in the prepared buffer solution, the solution obtained by sterilization by autoclaving was filled in 1 ml ampoules to prepare a muscle injection (Table 9).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.4%(W/V)0.4% (W / V) 인산이수소칼륨(KH2PO4)Potassium Dihydrogen Phosphate (KH 2 PO 4 ) 0.68%(W/V)0.68% (W / V) 수산화나트륨(NaOH)Sodium Hydroxide (NaOH) 0.16%(W/V)0.16% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 10:Example 10:

록소프로펜 나트륨, 나트륨 피로설파이트와 만니톨을 주사용 증류수에 용해시킨후 고온감압멸균법으로 멸균하여 얻은 용액을 1 ㎖ 앰플에 충진하여 근육주사제를 제조하였다(표 10).Muscle injection was prepared by dissolving roxofene sodium, sodium pyrosulphite and mannitol in distilled water for injection and then sterilizing by autoclaving in a 1 ml ampoule (Table 10).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.4%(W/V)0.4% (W / V) 만니톨Mannitol 5.0%(W/V)5.0% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

분말주사제의 제조Preparation of Powder Injection

실시예 11:Example 11:

록소프로펜 나트륨과 만니톨을 주사용 증류수에 용해시킨후 나트륨 피로설파이트를 첨가하여 완전히 용해시켰다. 이 용액을 무균여과하여 바이알에 넣고 동결 건조하여 건조분말 제품을 제조하였다. 사용시 이 건조분말 바이알에 별도로 포장된 주사용 증류수 1 ㎖를 가해 완전히 용해시킨후 근육주사제로 제조하였다(표 11).Sodium roxofene and mannitol were dissolved in distilled water for injection, followed by complete dissolution by addition of sodium pyrosulphite. The solution was sterile filtered and placed in a vial, lyophilized to prepare a dry powder product. In use, 1 ml of distilled water for injection, separately packaged, was added to this dry powder vial to completely dissolve and prepared as an intramuscular injection (Table 11).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.4%(W/V)0.4% (W / V) 만니톨Mannitol 20.0%(W/V)20.0% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 12:Example 12:

인산이수소칼륨과 수산화나트륨을 주사용 증류수에 용해시켜 pH 6.5의 인산염 완충용액을 제조하였다. 제조된 용액에 만니톨, 록소프로펜 나트륨 및 나트륨 피로설파이트를 완전히 용해시키고 무균여과하여 바이알에 넣고 동결건조하여 건조분말 제품을 제조하였다. 사용시 이 건조분말 바이알에 별도로 포장된 주사용 증류수 1 ㎖를 가해 완전히 용해시킨후 근육주사제로 제조하였다(표 12).Potassium dihydrogen phosphate and sodium hydroxide were dissolved in distilled water for injection to prepare a phosphate buffer at pH 6.5. Manitol, lysopropene sodium, and sodium pyrosulphite were completely dissolved in the prepared solution, aseptically filtered, put into a vial, and lyophilized to prepare a dry powder product. In use, 1 ml of distilled water for injection, separately packaged, was added to this dry powder vial to completely dissolve and prepared as a muscle injection (Table 12).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜 나트륨Roxofene sodium 6.81%(W/V)6.81% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.4%(W/V)0.4% (W / V) 인산이수소칼륨(KH2PO4)Potassium Dihydrogen Phosphate (KH 2 PO 4 ) 20.0%(W/V)20.0% (W / V) 수산화나트륨(NaOH)Sodium Hydroxide (NaOH) 0.06%(W/V)0.06% (W / V) 만니톨Mannitol 25.0%(W/V)25.0% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 13:Example 13:

록소프로펜과 탄산수소나트륨을 주사용 증류수에 용해시킨 용액이 1 ㎖가 되도록 조절하고 나트륨 피로설파이트를 첨가하여 완전히 용해시켰다. 이 용액을 무균여과하여 바이알에 넣고 동결건조하여 건조분말 제품을 제조하였다. 사용시 이 건조분말 바이알에 별도로 포장된 주사용 증류수 1 ㎖를 가해 완전히 용해시킨후 근육주사제로 제조하였다(표 13).The solution of lysopropene and sodium bicarbonate dissolved in distilled water for injection was adjusted to 1 ml and completely dissolved by addition of sodium pyrosulphite. The solution was sterile filtered and placed in a vial, lyophilized to prepare a dry powder product. In use, 1 ml of distilled water for injection, separately packaged, was added to this dry powder vial to completely dissolve and prepared as an intramuscular injection (Table 13).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜Roxofene 6.25%(W/V)6.25% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.4%(W/V)0.4% (W / V) 탄산수소나트륨(NaHCO3)Sodium bicarbonate (NaHCO 3 ) 2.13%(W/V)2.13% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실시예 14:Example 14:

록소프로펜과 수산화나트륨을 주사용 증류수에 용해시킨 용액이 1 ㎖가 되도록 조절하고 나트륨 피로설파이트를 첨가하여 완전히 용해시켰다. 이 용액을 무균여과하여 바이알에 넣고 동결건조하여 건조분말 제품을 제조하였다. 사용시 이 건조분말 바이알에 별도로 포장된 주사용 증류수 1 ㎖를 가해 완전히 용해시킨후 근육주사제로 제조하였다(표 14).The solution in which roxofene and sodium hydroxide were dissolved in distilled water for injection was adjusted to 1 ml and dissolved completely by addition of sodium pyrosulphite. The solution was sterile filtered and placed in a vial, lyophilized to prepare a dry powder product. In use, 1 ml of distilled water for injection, separately packaged, was added to this dry powder vial to completely dissolve and prepared as a muscle injection (Table 14).

록소프로펜 근육주사제 1 ㎖당 조성Composition per ml of Roxoprofen intramuscular injection 성분ingredient 함량content 록소프로펜Roxofene 6.25%(W/V)6.25% (W / V) 나트륨 피로설파이트Sodium pyrosulphite 0.4%(W/V)0.4% (W / V) 수산화나트륨(NaOH)Sodium Hydroxide (NaOH) 1.02%(W/V)1.02% (W / V) 주사용 증류수Distilled water for injection 전체 액량을 1 ㎖로 조절Adjust the total liquid volume to 1 ml

실험예 1: 랫트를 이용한 록소프로펜 정제 및 근육주사제의 약물혈중농도 비교실험Experimental Example 1 Comparative Test of Drug Blood Concentration of Loxoprofen Tablet and Intramuscular Injection Using Rat

실시예 1 등의 방법에 의해 제조한 록소프로펜 근육주사제에 대해 현재 시판중인 록소프로펜 정제(록소닌정)을 대조군으로 하여 록소프로펜의 혈중농도를 특정 병원체 부재의 수컷 6 주령 SD계 랫트를 이용하여 측정하였다.The blood concentration of roxofene is determined as a control for the roxofene penetrate intramuscular injection prepared by the method of Example 1 and the like. It was measured using an SD rat.

투여량은 대조군의 경우 랫트에 대해 10 mg/kg의 투여량으로 단회 경구로 투여하고, 실험군의 경우 랫트에 대해 5 mg/kg의 투여량으로 단회 근육주사로 투여하였다. 랫트의 혈액을 약물투여후 2 분, 5 분, 10 분, 20 분, 30 분, 60 분, 120 분 및 180 분간의 단위로 채취하여 전처리한후 혈중약물농도를 분석하였다. 그 결과를 록소프로펜의 혈중농도(㎍/㎖) 대 시간(min)으로 표시하였다.The dose was administered orally once at a dose of 10 mg / kg for rats in the control group and a single intramuscular injection at a dose of 5 mg / kg in rats in the experimental group. Rat blood was collected in units of 2 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 60 minutes, 120 minutes, and 180 minutes after drug administration and analyzed for blood drug concentrations. The results are expressed as blood concentration (µg / ml) versus time (min) of roxofene.

록소프로펜 정제 및 근육주사제의 혈중약물농도 비교실험결과Comparison of Plasma Drug Concentrations of Loxoprofen Tablets and Intramuscular Injections 시간(분)Minutes 실험군(근육주사제)의 혈중약물농도(㎍/㎖)Blood drug concentration in the experimental group (muscle injection) (㎍ / ㎖) 대조군(정제)의 혈중약물농도(㎍/㎖)Blood drug concentration of the control (tablet) (㎍ / ㎖) 22 4.04.0 4.14.1 55 4.54.5 5.55.5 1010 5.65.6 5.85.8 2020 6.56.5 7.47.4 6060 5.45.4 6.56.5 120120 4.14.1 5.05.0 180180 2.82.8 3.73.7

표 15에 나타낸 바와 같이, 실험군(근육주사제)의 약물을 대조군(정제)의 약물에 비해 50%의 양만을 투여하였으므로 혈중농도가 약간 낮게 나타나지만, 약물의 혈중농도 변화형태는 대조군(정제)과 실험군(근육주사제)이 유사한 곡선을 이루고 있음을 확인할 수 있었다(도 1 참조).As shown in Table 15, since the drug of the experimental group (muscle injection) was administered only 50% of the drug of the control group (tablet), the blood concentration was slightly lower, but the blood concentration of the drug was changed in the control group (tablet) and the experimental group. (Muscle injection) was confirmed to form a similar curve (see Fig. 1).

실험예 2: 근육주사제의 안정성 시험Experimental Example 2: Stability Test of Muscle Injection

실시예 1 등의 방법에 의해 제조한 록소프로펜의 근육주사제에 대해 각각 상온, 50 ℃ 및 60 ℃의 보관조건하에서 1 주일, 3 주일 및 4 주일간의 간격으로 시료를 채취하여 약물함량 및 pH의 변화를 측정하였으며, 그 결과를 표 16에 나타내었다.Samples of the intramuscular injection of roxofene prepared by the method of Example 1 were collected at intervals of 1 week, 3 weeks and 4 weeks under storage conditions at room temperature, 50 ° C. and 60 ° C., respectively. Was measured, and the results are shown in Table 16.

록소프로펜 근육주사제의 약물함량 변화Changes in Drug Content of Roxoprofen Muscle Injection 보관온도Storage temperature 초기Early 1 주후1 week later 3 주후3 weeks later 4 주후4 weeks later 상온(R.T)Room temperature (R.T) 100.1%100.1% 99.8%99.8% 99.7%99.7% 99.9%99.9% 50o50 o 99.6%99.6% 98.6%98.6% 99.5%99.5% 99.8%99.8% 60 ℃60 ℃ 99.6%99.6% 100.1%100.1% 99.3%99.3% 98.9%98.9%

록소프로펜 근육주사제의 pH 변화Changes in pH of Roxoprofen Intramuscular Injection 보관온도Storage temperature 초기Early 1 주후1 week later 3 주후3 weeks later 4 주후4 weeks later 상온(R.T)Room temperature (R.T) 6.466.46 6.436.43 6.436.43 6.426.42 50 ℃50 ℃ 6.446.44 6.446.44 6.446.44 6.446.44 60 ℃60 ℃ 6.446.44 6.446.44 6.446.44 6.456.45

표 16에 나타낸 바와 같이, 본 발명에 따른 록소프로펜 근육주사제의 경우 약물함량과 pH가 모두 변화없이 안정성이 일정하게 유지됨을 확인할 수 있었다.As shown in Table 16, in the case of the loxoprofen intramuscular injection according to the present invention it was confirmed that the stability of the drug content and pH is kept constant without any change.

실험예 3: 랫트를 이용한 록소프로펜 정제 및 근육주사제의 족부종 비교시험Experimental Example 3: Comparative test of foot edema of tablets and intramuscular injection of loxoprofen using rats

1) 실험동물: 특정 병원체 부재의 수컷 6 주령 SD계 랫트Experimental Animals: Male 6-week-old SD rats without specific pathogens

2) 시험물질 및 약물투여량: 부종 유발물질인 1% 카라기난 람다(carrageenan lamda) 타입 Ⅳ(Sigma Co.)을 시험동물 모델인 랫트의 발바닥 피하에 주입하여 족부종을 유발하였다. 록소프로펜 나트륨을 근육주사용으로 실시예 5 등의 방법에 따라 인산염 완충용액을 이용하여 5 mg/2 ㎖ 용액과 10 mg/10 ㎖ 용액을 제조하여 근육투여는 5 mg/2 ㎖/kg 용량으로, 경구투여는 10 mg/10 ㎖/kg 용량으로 각각 투여하였다.2) Test Substance and Drug Dose: An edema-inducing substance, 1% carrageenan lamda type IV (Sigma Co.), was injected subcutaneously into the plantar rat to induce foot edema. By intramuscular injection of lysopropene sodium, a 5 mg / 2 ml solution and a 10 mg / 10 ml solution were prepared using a phosphate buffer solution according to the method of Example 5, and the intramuscular administration was 5 mg / 2 ml / kg. At the dose, oral administration was administered at 10 mg / 10 mL / kg doses, respectively.

3) 시험방법 및 계산식: 랫트 좌측 뒷발의 발목 관절부위에 기준점을 표시한후 부종측정기(Hugo Sacks Coulbourn)를 사용하여 약물 투여전의 발부피를 측정하였다. 시험약물을 경구 또는 근육주사에 의해 투여하고 20 분후에 부종 유발물질인 1% 카라기난 용액을 좌측 뒷발에 각 개체당 0.1 ㎖ 용량으로 피하주사하였다. 부종유발물질 투여 2 시간 30 분후에 발의 부피를 측정하고 부종율과 부종억제율을하기 식에 의해 계산하였다:3) Test Methods and Formulas: After the reference point was marked on the ankle joint of the left hind paw of the rat, the foot volume before drug administration was measured using a HUGO Sacks Coulbourn. Twenty minutes after the test drug was administered by oral or intramuscular injection, a 1% carrageenan solution, an edema inducer, was injected subcutaneously in a 0.1 ml dose for each individual in the left hind paw. Two and a half hours after the edema-inducing substance, the volume of the foot was measured and the edema rate and edema inhibition rate were calculated by the following equation:

4) 평가기준: 각 약물의 부종억제율에 대해 무처치 대조군과의 유의성을 분산분석법(ANOVA)으로 검정하고, 유효성 수치가 0.05 이하(p<0.05)인 경우를 부종이 억제되었다고 판정하였다.4) Evaluation Criteria: The variance analysis (ANOVA) of the drug-free edema inhibition rate was tested by variance analysis (ANOVA), and it was determined that edema was suppressed when the efficacy value was 0.05 or less (p <0.05).

5) 부종율 및 부종억제율 시험결과: 족부종시험 결과를 표 17에 나타내었다.5) Edema rate and edema inhibition test results: Table 17 shows the results of foot edema test.

록소프로펜 정제 및 근육주사제의 족부종 비교시험 결과Foot edema comparison test of roxofene tablets and intramuscular injection 시험군Test group 투여경로Route of administration 체중당 약물투여용량Drug dosage per weight 시험동물수Number of test animals 부종율(%)Edema rate (%) 부종억제율(%)Edema inhibition rate (%) 대조군Control 비투여Nonadministration -- 4 마리4 horses 133.2±8.3133.2 ± 8.3 -- 록소프로펜 나트륨 주사제Roxofene sodium injection 근육주사Intramuscular injection 5 mg/kg5 mg / kg 4 마리4 horses 36.0±18.8* 36.0 ± 18.8 * 73.073.0 록소프로펜 나트륨 정제Roxofene sodium tablets 경구투여Oral administration 10 mg/kg10 mg / kg 4 마리4 horses 31.7±19.0* 31.7 ± 19.0 * 76.276.2

*: P<0.05 vs. 대조군단, 부종율은 평균치±표준편차로 표시하였다.*: P <0.05 vs. Control group, edema rate was expressed as the mean ± standard deviation.

표 17에 나타낸 바와 같이, 록소프로펜 나트륨을 5 mg/kg 용량으로 근육투여한 경우 부종억제율은 73.0%였으며, 10 mg/kg용량으로 경구투여한 경우 부종억제율은 76.2%으로서, 근육주사의 경우 경구투여시에 비해 체중당 50% 용량의 약물만을 투여하고도 부종억제율이 거의 비슷하게 나타남을 확인할 수 있었다.As shown in Table 17, the edema inhibition rate was 73.0% when intramuscularly administered loxoprofen sodium at 5 mg / kg dose, and the edema inhibition rate was 76.2% when administered orally at 10 mg / kg dose. In the case of oral administration, even when only 50% of the weight of the drug was administered, the edema inhibition rate was almost similar.

실험예 4: 마우스를 이용한 록소프로펜 정제 및 근육주사제의 진통효력 비교시험Experimental Example 4: Comparative test of analgesic efficacy of tablets of loxoprofen and intramuscular injection using mouse

1) 실험동물: 특정 병원체 부재의 수컷 5 주령 ICR계 마우스Experimental Animals: Male 5-week-old ICR mice without specific pathogens

2) 시험물질 및 약물투여량: 록소프로펜 나트륨을 근육주사용으로 실시예 5등의 방법에 따라 인산염 완충용액을 이용하여 5 mg/2 ㎖ 용액과 10 mg/10 ㎖ 용액으로 제조하여 근육투여는 5 mg/2 ㎖/kg 용량으로, 경구투여는 10 mg/10 ㎖/kg 용량으로 각각 투여하였다. 시험물질 투여 20 분후에 통증유발물질인 0.7% 아세트산 수용액(acetic acid in D.W)을 10 ㎖/kg 용량으로 복강투여하여 통증을 유발시키고, 5 분후부터 10 분 간격으로 몸부림(writhing) 횟수를 측정하였다.2) Test Substance and Drug Dose: Inject the roxofene sodium into the muscle using 5 mg / 2 ml solution and 10 mg / 10 ml solution using phosphate buffer solution according to the method of Example 5, etc. Administration was at a 5 mg / 2 ml / kg dose and oral administration at a 10 mg / 10 ml / kg dose, respectively. 20 minutes after administration of test substance, pain-causing substance was intraperitoneally administered 10% / kg of aqueous acetic acid in DW at 10 ml / kg dose to induce pain, and the number of writhing was measured at intervals of 10 minutes after 5 minutes. .

3) 진통효력 시험결과: 진통효력 시험결과를 표 18에 나타내었다.3) Analgesic efficacy test results: Table 18 shows the analgesic effect test results.

록소프로펜 정제 및 주사제의 진통효력 비교시험 결과Analyzes of Analgesic Effects of Roxoprofen Tablets and Injections 시험군Test group 투여경로Route of administration 체중당 약물투여용량Drug dosage per weight 시험동물수Number of test animals 몸부림횟수Writhing 통증억제율(%)Pain suppression rate (%) 대조군Control 비투여Nonadministration -- 18 마리18 horses 35.6±10.835.6 ± 10.8 -- 록소프로펜 나트륨 주사제Roxofene sodium injection 근육주사Intramuscular injection 5 mg/kg5 mg / kg 13 마리13 horses 16.5±10.4* 16.5 ± 10.4 * 53.753.7 록소프로펜 나트륨 정제Roxofene sodium tablets 경구투여Oral administration 10 mg/kg10 mg / kg 15 마리15 horses 17.7±8.0* 17.7 ± 8.0 * 64.064.0

*: P<0.05 vs. 대조군단, 몸부림횟수는 평균치±표준편차로 표시하였다.*: P <0.05 vs. In the control group, the number of writhing was expressed as the mean ± standard deviation.

표 18에 나타낸 바와 같이, 록소프로펜 나트륨을 5 mg/kg 용량으로 근육투여한 경우 통증억제율은 53.7%였으며, 10 mg/kg용량으로 경구투여한 경우 통증억제율은 64.0%으로서, 근육주사의 경우 경구투여시에 비해 체중당 50% 용량의 약물만을 투여하고도 통증억제율이 거의 비슷하게 나타남을 알 수 있다.As shown in Table 18, the pain inhibition rate was 53.7% when intramuscularly administered loxoprofen sodium at 5 mg / kg dose, and the pain inhibition rate was 64.0% when orally administered at 10 mg / kg dose. In the case of oral administration, even when only 50% of the weight per drug is administered, the pain suppression rate is almost similar.

본 발명에 따른 록소프로펜의 근육주사제는 경구투여가 곤란한 환자에게도 적용가능할뿐 아니라, 경구투여시보다 소량의 약물로도 동등 이상의 소염진통 효과를 얻을 수 있으며, 경피투여시 수반되는 부작용을 해소함과 동시에 속효성을 얻을 수 있다.The intramuscular injection of loxoprofen according to the present invention is applicable not only to patients who have difficulty in oral administration, but also can obtain an anti-inflammatory or analgesic effect equal to or more than a small amount of the drug compared to oral administration, and eliminates side effects associated with transdermal administration. And at the same time you can get a quick effect.

Claims (12)

유효성분으로서 하기 화학식 1의 록소프로펜 또는 그의 약제학적으로 허용되는 염을 함유하는 근육주사제 조성물:An intramuscular injection composition containing Roxoprofen of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient: [화학식 1][Formula 1] 제1항에 있어서, 록소프로펜의 약제학적으로 허용되는 염이 록소프로펜의 나트륨염인 조성물.The composition of claim 1, wherein the pharmaceutically acceptable salt of roxofene is the sodium salt of roxofene. 제1항에 있어서, 록소프로펜 또는 그의 약제학적으로 허용되는 염을 안정화제 또는 용해보조제와 함께 주사용수에 용해시킨후 멸균처리하여 제조되는 조성물.The composition of claim 1, wherein the composition is prepared by dissolving roxofene or a pharmaceutically acceptable salt thereof in water for injection with a stabilizer or dissolution aid and then sterilizing. 제3항에 있어서, 고온감압멸균법 또는 무균여과법에 의해 멸균처리하여 제조되는 조성물.The composition according to claim 3, which is prepared by sterilization by high temperature autoclaving or aseptic filtration. 제3항에 있어서, 주사용수는 주사용 증류수 또는 주사용 완충용액인 조성물.The composition of claim 3 wherein the water for injection is distilled water for injection or buffer for injection. 제5항에 있어서, 주사용 완충용액은 pH 3.5∼7.5 범위의 인산염 완충용액 또는 인산이수소나트륨(NaH2PO4)-구연산 완충용액인 조성물.6. The composition of claim 5, wherein the injectable buffer is a phosphate buffer in the range of pH 3.5-7.5 or sodium dihydrogen phosphate (NaH 2 PO 4 ) -citric acid buffer. 제6항에 있어서, 인산염은 나트륨염 또는 칼륨염 형태이거나 무수물 또는 수화물 형태이고, 구연산은 무수물 또는 수화물 형태인 조성물.The composition of claim 6 wherein the phosphate is in the form of sodium or potassium salts or in the form of anhydrides or hydrates, and the citric acid is in the form of anhydrides or hydrates. 제3항에 있어서, 안정화제는 나트륨 피로설파이트(sodium pyrosulfite), 중아황산나트륨(NaHSO3), 메타중아황산나트륨(Na2S2O3) 및 에틸렌디아민테트라아세트산(ethylenediaminetetraacetic acid)으로 구성된 그룹으로부터 선택되는 조성물.4. The stabilizer of claim 3 wherein the stabilizer is selected from the group consisting of sodium pyrosulfite, sodium bisulfite (NaHSO 3 ), sodium metabisulfite (Na 2 S 2 O 3 ) and ethylenediaminetetraacetic acid Composition. 제3항에 있어서, 용해보조제는 수산화나트륨(NaOH), 탄산수소나트륨(NaHCO3), 탄산나트륨(NaCO3), 수산화칼륨(KOH), 염산(HCl) 및 아세트산(CH3COOH)으로 구성된 그룹으로부터 선택되는 조성물.4. The dissolution aid according to claim 3 from the group consisting of sodium hydroxide (NaOH), sodium bicarbonate (NaHCO 3 ), sodium carbonate (NaCO 3 ), potassium hydroxide (KOH), hydrochloric acid (HCl) and acetic acid (CH 3 COOH). Composition selected. 제3항에 있어서, pH 3.5∼7.5 범위의 액제 조성물.The liquid formulation according to claim 3, which has a pH in the range of 3.5 to 7.5. 제3항에 있어서, 멸균처리후 동결건조시켜 제조되는 분말 조성물.The powder composition of claim 3, prepared by lyophilization after sterilization. 제1항에 있어서, 유효성분의 농도가 2∼20% 범위인 조성물.The composition of claim 1 wherein the concentration of the active ingredient is in the range of 2-20%.
KR10-2000-0076298A 2000-12-14 2000-12-14 Pharmaceutical composition for intramuscular injection containing loxoprofen KR100405161B1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR10-2000-0076298A KR100405161B1 (en) 2000-12-14 2000-12-14 Pharmaceutical composition for intramuscular injection containing loxoprofen
OA1200200244A OA12175A (en) 2000-12-14 2001-12-13 Pharmaceutical composition for intramuscular injection containing loxoprofen.
JP2002549235A JP2004515526A (en) 2000-12-14 2001-12-13 Loxoprofen-containing pharmaceutical composition for intramuscular injection
BR0108313-9A BR0108313A (en) 2000-12-14 2001-12-13 Pharmaceutical composition for intramuscular injection containing loxoprofen
UA2002086717A UA76097C2 (en) 2000-12-14 2001-12-13 Formulation for intramuscular injection containing loxoprofen
MXPA02007788A MXPA02007788A (en) 2000-12-14 2001-12-13 Pharmaceutical composition for intramuscular injection containing loxoprofen.
CNB018049494A CN1278672C (en) 2000-12-14 2001-12-13 Pharmaceutical composition for intramuscular injection containing loxoprofen
APAP/P/2002/002594A AP1530A (en) 2000-12-14 2001-12-13 Pharmaceutical composition for intramuscular injection containing loxoprofen.
AU2002222750A AU2002222750A1 (en) 2000-12-14 2001-12-13 Pharmaceutical composition for intramuscular injection containing loxoprofen
RU2002121772/15A RU2232572C2 (en) 2000-12-14 2001-12-13 Loxoprofen-containing pharmaceutical composition for intramuscular injections
PCT/KR2001/002161 WO2002047661A1 (en) 2000-12-14 2001-12-13 Pharmaceutical composition for intramuscular injection containing loxoprofen
ARP010105804A AR033596A1 (en) 2000-12-14 2001-12-14 PHARMACEUTICAL COMPOSITION FOR INTRAMUSCULAR INJECTION CONTAINING LOXOPROPHENE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2000-0076298A KR100405161B1 (en) 2000-12-14 2000-12-14 Pharmaceutical composition for intramuscular injection containing loxoprofen

Publications (2)

Publication Number Publication Date
KR20020046407A KR20020046407A (en) 2002-06-21
KR100405161B1 true KR100405161B1 (en) 2003-11-12

Family

ID=36691545

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-0076298A KR100405161B1 (en) 2000-12-14 2000-12-14 Pharmaceutical composition for intramuscular injection containing loxoprofen

Country Status (12)

Country Link
JP (1) JP2004515526A (en)
KR (1) KR100405161B1 (en)
CN (1) CN1278672C (en)
AP (1) AP1530A (en)
AR (1) AR033596A1 (en)
AU (1) AU2002222750A1 (en)
BR (1) BR0108313A (en)
MX (1) MXPA02007788A (en)
OA (1) OA12175A (en)
RU (1) RU2232572C2 (en)
UA (1) UA76097C2 (en)
WO (1) WO2002047661A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040054008A1 (en) 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US8227430B2 (en) 2007-09-04 2012-07-24 Meiji Seika Pharma Co., Ltd Injectable, injection solution, and injection kit preparation
EP2243477A1 (en) * 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol for parenteral application
JP2011225514A (en) * 2009-10-30 2011-11-10 Kowa Co Pharmaceutical composition containing loxoprofen or salt thereof
EP2926832A1 (en) 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical formulations of loxoprofen for topical use
EP2926810A1 (en) 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
WO2015165847A1 (en) 2014-04-29 2015-11-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of loxoprofen
EA201692424A1 (en) 2014-06-30 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. COMBINATION OF LOXOPROPHENE AND AGONIST OF GAMMA-AMINOIL ACID RECEPTORS
EP3197434A1 (en) 2014-09-24 2017-08-02 Sanovel Ilac Sanayi ve Ticaret A.S. Loxoprofen and antispastic drug combinations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740374A (en) * 1985-11-26 1988-04-26 Nitto Electric Industrial Co., Ltd. Anti-inflammatory analgesic adhesive preparation
KR19990037138A (en) * 1997-10-27 1999-05-25 타이도 나오카타 Intra-articular Dosages for Treating Joint Diseases
EP0947584A1 (en) * 1996-08-26 1999-10-06 Lead Chemical Company Ltd. Loxoprofen-containing preparation for external use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740374A (en) * 1985-11-26 1988-04-26 Nitto Electric Industrial Co., Ltd. Anti-inflammatory analgesic adhesive preparation
EP0947584A1 (en) * 1996-08-26 1999-10-06 Lead Chemical Company Ltd. Loxoprofen-containing preparation for external use
KR19990037138A (en) * 1997-10-27 1999-05-25 타이도 나오카타 Intra-articular Dosages for Treating Joint Diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
[Pharmacology, S.K.Gupta et al.,1998, 56, p137-143] *
[응용약물학회지,채주병 et al., 1999, 7(2), p.198-203] *
Pharmacological Research Vol.39, no.2, 1999, p.138-141 *

Also Published As

Publication number Publication date
MXPA02007788A (en) 2002-10-17
RU2232572C2 (en) 2004-07-20
AR033596A1 (en) 2003-12-26
CN1400892A (en) 2003-03-05
AP2002002594A0 (en) 2002-09-30
JP2004515526A (en) 2004-05-27
WO2002047661A1 (en) 2002-06-20
CN1278672C (en) 2006-10-11
OA12175A (en) 2006-05-09
UA76097C2 (en) 2006-07-17
AU2002222750A1 (en) 2002-06-24
KR20020046407A (en) 2002-06-21
BR0108313A (en) 2003-03-11
AP1530A (en) 2006-01-04

Similar Documents

Publication Publication Date Title
ES2340939T3 (en) USE OF TREPROSTINIL TO TREAT NEUROPATIC DIABETIC FOOT ULCERS.
US6291527B1 (en) Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
ES2304798T3 (en) PROPIONIC ACID SALTS (R) -2- (3-BENZOILFENIL) AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
ES2244625T3 (en) USE OF BIGUANIDA DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT WITH CICATRIZING EFFECT.
US20070141182A1 (en) Combination of multiple nonteroidal antiinflammatory drugs and muscle relaxants for local treatment of musculoskeletal pain
KR100405161B1 (en) Pharmaceutical composition for intramuscular injection containing loxoprofen
JPS6388122A (en) Blend of quick absorption and action sulindac or sodium sulindac together with base
ZA200105275B (en) New use of melagatran.
KR100709528B1 (en) Drug composition for blood sugar control
WO1992003130A1 (en) Use of aryl hydroxyurea compounds for the treatment of atherosclerosis
ES2237625T3 (en) USE OF A HYDANTOIN DERIVATIVE IN A PHARMACEUTICAL COMPOSITION AGAINST HYPOALBUMINEMIA.
NZ542218A (en) Pharmaceutical composition comprising 5-methyl-2-2&#39;-(chloro-6&#39;-fluoroanilino)phenylacetic acid
TW201002368A (en) Unit dose formulations of ketorolac for intranasal administration
US20210252025A1 (en) Synergic pharmaceutical combination of a selective inhibitor of cyclooxygenase-2 and an anthraquinone derivative
AR062894A1 (en) FORMULATIONS FOR THERAPEUTIC ESTIMULATION HORMONE THERAPEUTIC ADMINISTRATION (THS)
US9687549B2 (en) Topical pharmaceutical gel composition of diclofenac sodium
WO2009157010A1 (en) An intravenous drug delivery system
RU2345775C1 (en) Nonsteroid antiinflammatory medicinal agent
BR112021002156A2 (en) wart treatment
CA2542509A1 (en) Salts of pharmacologically active compounds
US11642328B2 (en) Creatine, its derivatives, compositions and methods of use thereof
TWI301413B (en) Pharmaceutical composition for intramuscular injection containing loxoprofen
JPH0242027A (en) Transmucosal absorbefacient and pernasal administration agent using said absorbefacient
ITBO20100731A1 (en) SOLID COMPOSITIONS INCLUDING NON-STEROID IDEAS, PROCESSES FOR THEIR PREPARATION AND THEIR USE.
US20020115661A1 (en) Method for treating chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121011

Year of fee payment: 12

A101 Application to extend term of patent right by permit
LAPS Lapse due to unpaid annual fee